TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Price, Forecast & Analysis

NASDAQ:TRIB • US8964385046

0.72 USD
0 (0%)
Last: Mar 2, 2026, 11:27 AM

TRIB Key Statistics, Chart & Performance

Key Statistics
Market Cap13.47M
Revenue(TTM)61.55M
Net Income(TTM)-31.79M
Shares18.71M
Float369.80K
52 Week High17.2
52 Week Low0.61
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-2.68
PEN/A
Fwd PEN/A
Earnings (Next)04-03
IPO1992-10-21
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
TRIB short term performance overview.The bars show the price performance of TRIB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40 -50

TRIB long term performance overview.The bars show the price performance of TRIB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TRIB is 0.72 USD. In the past month the price decreased by -18.34%. In the past year, price decreased by -80.31%.

TRINITY BIOTECH PLC-SPON ADR / TRIB Daily stock chart

TRIB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
TRIB Full Technical Analysis Report

TRIB Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to TRIB. TRIB may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TRIB Full Fundamental Analysis Report

TRIB Financial Highlights

Over the last trailing twelve months TRIB reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 41.07% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.91%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-12.04%
Sales Q2Q%16.15%
EPS 1Y (TTM)41.07%
Revenue 1Y (TTM)8.31%
TRIB financials

TRIB Forecast & Estimates

For the next year, analysts expect an EPS growth of 65.8% and a revenue growth 10.13% for TRIB


Analysts
Analysts85.71
Price TargetN/A
EPS Next Y65.8%
Revenue Next Year10.13%
TRIB Analyst EstimatesTRIB Analyst Ratings

TRIB Ownership

Ownership
Inst Owners24.88%
Ins OwnersN/A
Short Float %69.01%
Short Ratio0.06
TRIB Ownership

TRIB Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.8202.318B
ISRG INTUITIVE SURGICAL INC48.38178.812B
SYK STRYKER CORP25.6148.172B
BSX BOSTON SCIENTIFIC CORP21.62113.97B
IDXX IDEXX LABORATORIES INC42.5352.44B
BDX BECTON DICKINSON AND CO11.0250.281B
EW EDWARDS LIFESCIENCES CORP29.0250.178B
GEHC GE HEALTHCARE TECHNOLOGY15.9638.406B
RMD RESMED INC20.4837.332B
DXCM DEXCOM INC28.5428.639B

About TRIB

Company Profile

TRIB logo image Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Company Info

TRINITY BIOTECH PLC-SPON ADR

Ida Business Park, Bray, Co Wicklow

DUBLIN WICKLOW IE

CEO: Ronan O'Caoimh

Employees: 401

TRIB Company Website

TRIB Investor Relations

Phone: 1135312955111

TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ

What does TRIB do?

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.


Can you provide the latest stock price for TRINITY BIOTECH PLC-SPON ADR?

The current stock price of TRIB is 0.72 USD.


What is the dividend status of TRINITY BIOTECH PLC-SPON ADR?

TRIB does not pay a dividend.


What is the ChartMill rating of TRINITY BIOTECH PLC-SPON ADR stock?

TRIB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


On which exchange is TRIB stock listed?

TRIB stock is listed on the Nasdaq exchange.


Can you provide the ownership details for TRIB stock?

You can find the ownership structure of TRINITY BIOTECH PLC-SPON ADR (TRIB) on the Ownership tab.


What is the outstanding short interest for TRINITY BIOTECH PLC-SPON ADR?

The outstanding short interest for TRINITY BIOTECH PLC-SPON ADR (TRIB) is 69.01% of its float.